Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 14
Submit an article Journal homepage
153
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases

Paolo Elia Coppolaa IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy;b Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italia
,
Alessandro Broccolia IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy;b Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, ItaliaORCID Iconhttps://orcid.org/0000-0001-5633-7313
ORCID Icon,
Lisa Argnania IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy;b Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, ItaliaORCID Iconhttps://orcid.org/0000-0003-4225-4626
ORCID Icon,
Beatrice Casadeia IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy;b Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italia
,
Vittorio Stefonia IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy;b Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italia
,
Clara Bertuzzic Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
,
Elena Sabattinic Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
&
Pier Luigi Zinzania IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy;b Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, ItaliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2112-2651
ORCID Icon show all
Pages 3540-3543 | Received 03 Jun 2021, Accepted 22 Jul 2021, Published online: 04 Aug 2021

References

  • Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2017.
  • Woyach JA, Bojnik E, Ruppert AS, et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)). Blood. 2014;123(8):1207–1213.
  • Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88–94.
  • Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.
  • Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.
  • Imbruvica (ibrutinib) [package insert]. Pharmacyclics LLC. 2019.
  • Mato AR, Hill BT, Lamanna N, et al. Optimal sequencing of ibrutinib, idelalisib, ad venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol. 2017;28(5):1050–1056.
  • Hampel PJ, Call TG, Rabe KG, et al. Disease flare during temporary interruption of ibrutinib therapy in patients with chronic lymphocytic leukemia. Oncologist. 2020;25(11):974–980.
  • Byrd JC, Furman RR, Coutre SE, et al. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res. 2020;26(15):3918–3927.
  • Marostica E, Sukbuntherng J, Loury D, et al. Population pharmacokinetic model of ibrutinib, a bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol. 2015;75(1):111–121.
  • Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129(19):2612–2615.
  • Hampel PJ, Cherng HJ, Call TG, et al. Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Adv. 2020;4(18):4508–4511.
  • Kadri S, Lee J, Fitzpatrick C, et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 2017;1(12):715–727.
  • Boriani G, Corradini P, Cuneo A, et al. Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding. Hematol Oncol. 2018;36(4):624–632.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.